Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GadaCAD 1: Gadobutrol-enhanced CMRI for CAD Detection
NCT01890421Phase 3Completed
- Sponsor
- Bayer
- Start
- Jul 2013
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of gadobutrol in coronary artery disease (CAD), sponsored by Bayer. Primary endpoints: Sensitivity for Detection of Significant CAD (Blinded Readers), Specificity for Exclusion of Significant CAD (Blinded Readers) and 1 more. Started Jul 2013; status: completed.
02
Drugs
gadobutrol
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01890421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01890421.